

Haematologica
HAEMATOL/2018/187617
Version 3

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide
for the treatment of patients with relapsed or refractory peripheral T-cell
lymphoma

Paolo Strati, Dai Chihara, Yasuhiro Oki, Luis E. Fayad, Nathan Fowler,
Loretta Nastoupil, Jorge E. Romaguera, Felipe Samaniego, Naveen
Garg, Lei Feng, Emily T. Wesson, Charnelle E. Ruben, Mildred D.
Stafford, Yago Nieto, Issa F. Khouri, Chitra Hosing, Sandra B.
Horowitz, Rammurti T. Kamble, and Michelle A. Fanale

Disclosures: Funding: Celgene Corporation This work was supported in part by The MD
Anderson Cancer Center Support Grant (P30 CA016672).

Contributions: MAF designed the study, analyzed the data, provided clinical care to
patients, and wrote the paper; PS and DC analyzed data and wrote the paper; YO, LEF,
NF, LN, YER, FS, YN, IFK and RTK provided clinical care to patients and coauthored the
paper; LF wrote the statistical design of the study, analyzed data and wrote the paper;
ETW, CER and MDS collected the data and coauthored the paper.